Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504696 | 0.74 | HPGD (0.38) | KDM4EALDH1A1HPGD | |
| SCHEMBL3741710 | 0.70 | SSTR4 (0.39) | KDM4EALDH1A1HPGD | |
| SCHEMBL3838214 | 0.70 | ESR1 (0.45) | ALDH1A1ESR1ESR2AR | |
| SCHEMBL7463280 | 0.70 | FFAR1 (0.38) | — | |
| SCHEMBL8823997 | 0.69 | ESR1 (0.40) | KDM4EALDH1A1HPGDESR1ESR2 | |
| SCHEMBL580699 | 0.68 | GABRA1 (0.56) | KDM4EALDH1A1HSD17B10GABRA1GABRB2 | |
| SCHEMBL29644929 | 0.68 | GABRA1 (0.56) | KDM4EALDH1A1HSD17B10GABRA1GABRB2 | |
| SCHEMBL29376862 | 0.68 | GABRA1 (0.45) | KDM4EALDH1A1HPGDHSD17B10ESR1 | |
| SCHEMBL920467 | 0.68 | GABRA1 (0.45) | KDM4EALDH1A1HPGDHSD17B10ESR1 | |
| SCHEMBL11836435 | 0.67 | ATM (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8505730-B2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | JR CHEM, LLC (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120312717-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | JR CHEM, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-8273791-B2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | JR CHEM, LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2087880-A2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | Jr Chem, LLC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090176876-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | JR CHEM, LLC (US) | 2009-07-09 | — | — | US | disclosed |
| US-6960347-B2 | Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives | L'OREAL (FR) | 2005-11-01 | — | — | US | disclosed |
| US-20010036446-A1 | Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives | L'OREAL (FR) | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176876-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | RARG, RARA, RXRG | KDM4E 3387/4885ALDH1A1 368/4885HPGD 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.